Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of FRTX-02 in Healthy Subjects and Subjects With Atopic Dermatitis
NCT05382819Phase 1Terminated
- Sponsor
- Fresh Tracks Therapeutics
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FRTX-02 in atopic dermatitis (AD) (6 arms), sponsored by Fresh Tracks Therapeutics. Primary endpoint: The number of participants with treatment-emergent adverse events. Started May 2022; status: terminated.
02
Drugs
FRTX-02
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05382819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382819.